Roman Butler Fullerton & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Roman Butler Fullerton & Co’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$713K	Buy	1,606 +2	+0.1%	+$933	0.2%	124
2025 Q4	$750K	Buy	1,604 +10	+0.6%	+$4.31K	0.2%	123
2025 Q3	$665K	Sell	1,594 -1,983	-55%	-$829K	0.18%	130
2025 Q2	$1.68M	Buy	3,577 +489	+16%	+$225K	0.5%	47
2025 Q1	$1.55M	Buy	3,088 +1,521	+97%	+$709K	0.6%	41
2024 Q4	$695K	Sell	1,567 -83	-5%	-$38.5K	0.22%	106
2024 Q3	$799K	Sell	1,650 -1	-0.1%	-$480	0.24%	98
2024 Q2	$811K	Buy	1,651 +5	+0.3%	+$2.17K	0.26%	88
2024 Q1	$658K	Buy	1,646 +301	+22%	+$127K	0.25%	97
2023 Q4	$578K	Sell	1,345 -4,142	-75%	-$1.53M	0.23%	110
2023 Q3	$2.04M	Sell	5,487 -410	-7%	-$143K	0.96%	26
2023 Q2	$2.11M	Buy	5,897 +456	+8%	+$154K	0.97%	25
2023 Q1	$1.81M	Sell	5,441 -492	-8%	-$148K	0.9%	23
2022 Q4	$1.85M	Sell	5,933 -72	-1%	-$21.9K	0.96%	22
2022 Q3	$1.77M	Sell	6,005 -602	-9%	-$173K	1.13%	18
2022 Q2	$1.94M	Buy	6,607 +5,277	+397%	+$1.41M	1.07%	20
2022 Q1	$347K	Buy	+1,330	New	+$316K	0.16%	144
2021 Q3	–	Sell	-1,185	Closed	-$239K	–	197
2021 Q2	$239K	Buy	1,185 +223	+23%	+$46.6K	0.12%	172
2021 Q1	$213K	Buy	+962	New	+$211K	0.11%	191
2020 Q4	–	Sell	-4,008	Closed	-$1.09M	–	180
2020 Q3	$1.09M	Sell	4,008 -337	-8%	-$93K	0.71%	45
2020 Q2	$1.26M	Buy	4,345 +38	+0.9%	+$10.3K	0.9%	30
2020 Q1	$1.02M	Buy	4,307 +2,181	+103%	+$500K	0.9%	31
2019 Q4	$465K	Buy	+2,126	New	+$430K	0.31%	101
2019 Q1	–	Sell	-2,405	Closed	-$447K	–	185
2018 Q4	$447K	Buy	+2,405	New	+$417K	0.38%	98

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Roman Butler Fullerton & Co's VRTX Position: Q1 2026 in Review

Roman Butler Fullerton & Co increased its Vertex Pharmaceuticals (VRTX) stake by 0.12% in Q1 2026, buying an estimated $933 and bringing the position to 1,606 shares worth $713K. The position accounts for 0.2% of the portfolio, ranked #124.

Roman Butler Fullerton & Co first reported a position in VRTX in Q4 2018 and has held it in 24 quarters since. The position peaked at $2.11M in Q2 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Roman Butler Fullerton & Co held 1,606 shares of Vertex Pharmaceuticals worth $713K as of Q1 2026.
Roman Butler Fullerton & Co bought 2 Vertex Pharmaceuticals shares in Q1 2026, an estimated $933.
Vertex Pharmaceuticals made up 0.2% of Roman Butler Fullerton & Co's portfolio in Q1 2026, its #124 holding.
Roman Butler Fullerton & Co first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 24 quarters since.
Roman Butler Fullerton & Co's Vertex Pharmaceuticals position peaked at $2.11M in Q2 2023.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Roman Butler Fullerton & Co's 13F filing for Q1 2026, filed 30 Apr 2026.